[LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
D000726:Androgen Antagonists / Q000008:administration & dosage*; D000818:Animals; D002064:Buserelin / Q000008:administration & dosage*; D003534:Cyproterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017373:Cyproterone Acetate; D004285:Dogs; D004359:Drug Therapy, Combination; D005485:Flutamide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D051381:Rats; D011956:Receptors, Cell Surface / Q000187:drug effects; D011966:Receptors, LHRH
D000726:Androgen Antagonists; D011956:Receptors, Cell Surface; D011966:Receptors, LHRH; D017373:Cyproterone Acetate; D005485:Flutamide; D003534:Cyproterone; D002064:Buserelin
LHRH-Agonisten in Kombination mit Antiandrogenen zur Behandlung des metastasierenden Prostatakarzinoms.